VX-548 – Talk Bio

Vertex Pharmaceuticals Surpasses Q3 Expectations, Boosts Annual Revenue Forecast on Strong Cystic Fibrosis Sales

6 months ago talkbio0Tagged Casgevy, Cystic Fibrosis, earnings, full-year, Genetic Therapy, revenue guidance, Suzetrigine, Trikafta sales, vanzacaftor triple, VX-548

Vertex Pharmaceuticals, Q3 2024 earnings, Cystic fibrosis treatments, Trikafta sales, Full-year revenue guidance, Genetic therapies, Vanzacaftor triple, Suzetrigine (VX-548), Casgevy

Vertex’s Non-Opioid Pain Drug, Suzetrigine (VX-548), Shows Promising Results in Phase III Trials, Aiming for FDA Approval

6 months ago talkbio0Tagged Acute onset pain, Approved, non-opioid pain drug, Opioids, Phase 3 Clinical Trials, Suzetrigine, United States Food and Drug Administration, VX-548

Non-opioid pain drug, Suzetrigine (VX-548), Vertex Pharmaceuticals, Phase III trials, acute pain, FDA approval, opioid alternative

Vertex Initiates FDA Rolling Review for Non-Opioid Pain Medication Suzetrigine (VX-548)

1 year ago talkbio0Tagged Acute onset pain, Non-opioid painkiller, Rolling Review, Suzetrigine, United States Food and Drug Administration, VX-548

Vertex Pharmaceuticals, Suzetrigine (VX-548), Non-opioid painkiller, FDA rolling review, Acute pain

Promising Vertex Pain Med Points to New Era for Analgesics

1 year ago talkbio0Tagged Analgesics, Analgesics, Opioid, aspects of adverse effects, Effectiveness, historical period, VX-548

historical period, Analgesics, Opioid, VX-548, Analgesics, Effectiveness, aspects of adverse effects